GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Clinical trial NCT06558773 · RECRUITING
Trial details
- NCT number
- NCT06558773
- Sponsor
- Chinese PLA General Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-01
- Primary completion
- 2027-03-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.